Assessment of risks associated with cardiovascular gene therapy in human subjects.
about
Gene therapy for peripheral arterial diseaseGene therapy for peripheral arterial diseaseGene Therapy for Cardiovascular DiseaseIndirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategy.Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemiaGene therapy for cerebral vascular disease: update 2003.Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.Adult stem cell therapy for heart failure.Gene therapy for cardiovascular angiogenesis.Cardiovascular gene delivery: The good road is awaitingCardiovascular gene therapy: current status and therapeutic potential.Targeting cerebral arteries for gene therapy.New vectors and strategies for cardiovascular gene therapy.Angiogenic and antiangiogenic gene therapy.Gene therapy in the treatment of heart failure.Brain-derived neurotrophic factor: a newly described mediator of angiogenesis.Engineering blood vessels by gene and cell therapy.Current strategies for myocardial gene delivery.Gene and stem cell therapy in peripheral arterial occlusive disease.In vivo properties of the proangiogenic peptide QKHuman studies of angiogenic gene therapy.Adenovirus-mediated transfer of VEGF into marrow stromal cells combined with PLGA/TCP scaffold increases vascularization and promotes bone repair in vivo.Stem cell-mediated neovascularization in heart repair.Gene therapy and angiogenesis in patients with coronary artery disease.Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.Non-invasive bioluminescence imaging of myoblast-mediated hypoxia-inducible factor-1 alpha gene transferTissue-engineered provisional matrix as a novel approach to enhance diabetic wound healing.VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.Treatment of heart failure by calcium cycling gene therapy.Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts.Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector.Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb.Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth.Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization.
P2860
Q24187841-874FC945-2D70-4043-A74D-FF4525FB0031Q24246814-FCEE46C2-FB3F-4902-8A6E-11617436B872Q24791063-966E1A90-EEBE-447C-B53E-4C4282BBDB91Q33977026-BEFF5ED5-B6F5-40C5-8C7C-D6341E8F4B79Q34667599-90E66353-06A5-4A5B-8827-930DF1DC5D85Q34788546-B2BFF3A1-0651-44C3-9A1A-4D3C386F37A0Q35045240-24A87935-E205-4E6F-8D30-B7621C133D38Q35080395-AA1DEBEC-595F-4656-94F9-D5F93B37AAC3Q35093601-FD800DD3-21C9-48D5-9EE9-1051A33B35FBQ35164797-B993D875-6434-4C19-8917-A12D0215355DQ35915765-6F13362E-DC7A-4B98-986B-C750950EA1FEQ35995220-6A30D70B-B34C-4220-96E1-128D3C24F5F7Q36075172-07D7F529-8A78-4C9B-8197-7225530842C1Q36174173-F43189F8-393F-4F15-9FDD-13E10E737A63Q36288905-65D39B25-515B-4040-91D3-18E4FAD66110Q36786243-8B11EBA6-6A20-486C-ABB1-8B8401B34613Q36812099-6DCF6807-720C-4E4E-9279-974B3D0532F4Q36909367-94B611D7-E236-4951-8668-972750F44642Q36931967-B1676B31-5264-431F-B48B-8A7C91EB6B87Q37204529-2C927D2C-6CA3-4E0D-86AB-0F52170B5691Q37242381-DFA15B8A-0B93-44A2-9FEC-264F4C6D2CD4Q37406656-3B16F555-3F05-45F9-A0B9-3B9B31E6896AQ37636817-8965F362-7DE9-4DBC-B8B3-3D11628C1B12Q37665063-0F9C5222-8B34-4FA2-BB1D-D2A9377C12A2Q37776515-01B4D311-ACC8-4394-9D65-08C205BD76C3Q38081027-0CB13A50-CBEE-4250-B468-0D8B4EF5ED76Q39602637-822314CA-C500-4249-BAAE-9CA00E92D75DQ39677727-53050BB7-B8C1-4348-8D22-B02BE3495B73Q39741051-BF86A962-D7B2-4F38-9D4D-0FDA56EC7DCCQ40199219-E7780356-CC13-4A67-8E11-0E34BF651323Q40553670-84095850-2AC5-4426-B10D-A41110D5DCB3Q40607304-5278728C-F7AA-4DD8-B443-06259B3D8DD8Q40703867-B3F84BE8-E43C-4F5D-A8EB-6A225DA11434Q43619839-47C378A8-7C7C-4979-9ED0-640FDC740CF4Q45871974-A31581EB-92F2-461E-B521-2A4099CBB556Q45876829-11E1569C-6C74-41D5-98CE-1F2097F14390Q51370544-A0B8EA39-6029-4AD2-9B70-3645A08F21B7
P2860
Assessment of risks associated with cardiovascular gene therapy in human subjects.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@ast
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@en
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@nl
type
label
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@ast
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@en
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@nl
prefLabel
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@ast
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@en
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@nl
P2093
P921
P356
P1433
P1476
Assessment of risks associated with cardiovascular gene therapy in human subjects.
@en
P2093
P304
P356
10.1161/HH1701.096259
P577
2001-08-01T00:00:00Z